osimertinib: a potential new standard of care for advanced egfr-mutated nsclc | suresh ramalingam
Published 5 years ago • 58 plays • Length 6:50Download video MP4
Download video MP3
Similar videos
-
2:57
osimertinib poised to change standard of care treatment for patients with locally advanced egfr-...
-
1:50
researcher comment: positive os data for osimertinib in flaura trial | suresh ramalingam
-
6:08
flaura study: a new standard of care for patients with egfr mutated nsclc
-
1:40
dr. ramalingam on the role of osimertinib in egfr t790m-positive advanced nsclc
-
5:14
new standard for treating stage 4 egfr nsclc
-
8:44
flaura final analysis: osimertinib for first-line egfrm nsclc
-
2:04
dr. suresh ramalingam on frontline osimertinib data in egfr nsclc
-
6:06
osimertinib, the standard for egfr nsclc
-
0:47
suresh ramalingam, md, on how the flaura trial may impact care for egfr-mutated nsclc
-
3:31
osimertinib plus gefitinib for treatment of egfr-mutated non-small cell lung cancer
-
3:30
osimertinib for uncommon egfr mutations in nsclc
-
0:48
investigating osimertinib for brain activity in egfr-mutated lung cancer
-
9:49
osimertinib as frontline therapy for egfr-positive nsclc
-
2:34
dr. ramalingam on flaura findings in egfr-mutant nsclc
-
2:21
osimertinib ipilimumab in egfr-mutated nsclc
-
4:17
highlights on amivantamab after progression on osimertinib in egfr-mutated nsclc: mariposa-2
-
3:52
is adjuvant chemotherapy in egfr mutated nsclc still required?
-
0:48
new standard of care for lung cancer patients with egfr mutations
-
3:22
osimertinib plus chemotherapy shows superior results versus osimertinib alone for egfr-mutated a...